跳至主要内容
临床试验/CTRI/2017/10/010125
CTRI/2017/10/010125已完成不适用

Multi-centric Study for Screening and detection of oral potentially malignant disorders (OPMD) non-invasively by fluorescence and diffuse reflectance imaging with OralScan camera, and development of an algorithm for tissue discrimination

Sascan Meditech Pvt Ltd2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2017年10月25日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,000
试验地点
2
主要终点
Testing the accuracy of the device to locate the most malignant site in a lesion for biopsy.

研究概览

简要总结

The current screening modality practiced in India for detection of oral cancer is visual examination with white light. However, with white light examination, clinicians find it very challenging to locate the most malignant site for biopsy, leading to multiple biopsies or under-diagnosis  and unnecessary biopsies.  Sascan Meditech Pvt Ltd has developed a non-invasive device (OralScan) based on tissue fluorescence and diffuse reflectance imaging  to screen and detect oral precancers in real time. The device consists of multiple LEDs to illuminate the tissue and a monochrome camera to capture multiple images on sequential switching of these LEDs.  The device is connected to a tablet or PC for control using proprietary software. which also takes care of image processing and analysis. The primary purpose of the study is to test the capability of the device to visualize oral potentially malignant diseases (OPMD) of the oral cavity  and identify the most malignant site in the lesion for tissue biopsy, so that under-diagnosis is avoided.  This would be carried out by comparing the accuracy of the current practice with that of the device in this trial. No biopsy will be taken from healthy subjects. The fluorescence images and diffuse reflectance image ratios will be correlated with pathological data and an algorithm would be developed for determining the grade of cancer in real time.  The diagnostic accuracy of the device will also be assessed.  It is hoped that device would evolve as a biopsy guidance tool for clinicians and avoid the large number of false negatives and false positives associated with current practice and help reduce oral cancer burden.

研究设计

研究类型
Observational

入排标准

年龄范围
20.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Patients presenting with oral potentially malignant disorder (OPMD) lesions such as leukoplakia, erythroplakia, oral sub mucous fibrosis (OSMF), dysplasia and moderate to well differentiate squamous cell cancer.
  • 2.Healthy Volunteers without tobacco/pan/gutka/arrecanut/cigarette or beedi smoking/alcohol habits and any visible symptoms of other diseases or tissue inflammation in the oral cavity.

排除标准

  • 1.Previous treatments for cancer.
  • 2.Patients with systemic conditions that contraindicates biopsy.
  • 3.Recent application of any medication orally for at least four weeks.
  • 4.Patients not willing to participate.

结局指标

主要结局

Testing the accuracy of the device to locate the most malignant site in a lesion for biopsy.

时间窗: Two weeks of patient enrollment

次要结局

  • 1. Development of an algorithm to discriminate different types and grade cancer.(2. Determining the diagnostic accuracy of the device for discrimination of OPMD)

研究者

发起方
Sascan Meditech Pvt Ltd
申办方类型
Other [Medical Device Company]

研究点 (2)

Loading locations...

相似试验